BenevolentAI Drug Programmes Our advanced in-house pipeline demonstrates the utility of our technology and unique approach in generating valuable drug programmes. Disease Area Target ID Chemistry & Lead Optimisation Preclinical Phase 1 Phase 2 Atopic Dermatitis Ulcerative Colitis Amyotrophic Lateral Sclerosis Inflammatory Bowel Disease Glioblastoma Multiforme CNS Diseases Nonalcoholic Steatohepatitis (NASH) Oncology Antiviral Nonalcoholic Steatohepatitis (NASH) Oncology Oncology Chronic Kidney Disease AstraZeneca Idiopathic Pulmonary Fibrosis AstraZeneca 10+ Early Discovery Programmes (multiple indications & targets in therapy areas such as Oncology, Immunology, CNS, GI, Metabolic Disorders and Others) Case Studies Atopic Dermatitis Ulcerative Colitis Glioblastoma Multiforme ALS DERMATOLOGY Atopic Dermatitis Atopic Dermatitis is the most prevalent type of eczema. The drug we developed to treat the inflammation and itch associated with the disease is currently being tested in human clinical trials. View Case Study LICENSING Drug development licensing partnerships Our pipeline demonstrates the utility of the Benevolent Platform™, and we are actively exploring strategic licensing partnerships and late-stage development and commercialisation partnerships to deliver our medicines to patients in need. CONTACT US → COLLABORATIONS → OUR APPROACH We innovate at every stage of the drug discovery process By fusing artificial and human intelligence, we empower scientists to uncover new relationships between diseases and symptoms, drugs and their effects and the subgroups of patients who will respond to treatment. WHAT WE DO → PARTNERING → DRUG PROGRAMMES CAREERS COVID-19 DATA DIVERSITY INITIATIVE CONTACT US → Company Registration: 09781806 Terms & Conditions Privacy & Cookies Policy OUR APPROACH DRUG PROGRAMMES PARTNERING ABOUT US JOIN US NEWS